Novo Nordisk shares rallied on Tuesday as a maker of a weight-loss drug alternative confirmed it won’t be selling it for much ...
4h
Axios Vitals on MSNMedicare spending on diabetes drugs surged in 5 years: IGMedicare spending on 10 diabetes drugs, including popular GLP-1s, more than quadrupled over a five-year period and could ...
Shortages of Ozempic and Wegovy that have been in place for more than two years have been resolved, as supplies of the popular diabetes and obesity treatments continue to improve, federal regulators ...
The Food & Drug Administration announced last week that the Ozempic and Wegovy shortage for Novo Nordisk‘s (NYSE:NVO) was ...
We recently published a list of Renaissance Technologies Portfolio: Top 10 Stock Picks. In this article, we are going to take ...
1d
Axios on MSNCopycat Ozempic makers brace for crackdownMakers of copycat weight-loss drugs and digital health companies that sell them are bracing for upheaval now that the Food ...
President Donald Trump has issued a stringent warning to pharmaceutical companies, advising them to repatriate their manufacturing to the US or face the possibility of tariffs.
The current state of health services highlights crucial sectors facing disruptions and developments, from US foreign aid freezes affecting disease control supply chains, to the FDA's actions on new ...
High-end brands are churning through creative directors as they try to revive sales.
The U.S. Food and Drug Administration said on Friday there was no longer a shortage of Novo Nordisk's popular weight-loss and ...
The Justice Department has launched an investigation into the company's Medicare billing practices, [The Wall Street Journal reported]( ...
European shares settled near a record high on Friday and marked their longest streak of weekly gains in nearly a year, The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results